Julie Krop Acquires Shares in Aquestive Therapeutics

Julie Krop, an insider at Aquestive Therapeutics, Inc. (NasdaqGM: AQST), purchased 25,000 shares of the company on June 23, 2026. The shares were acquired at an average price of $0.71 each, making the total transaction worth $17,750. This purchase was not part of a pre-planned trading arrangement.

Insider Buying and Selling at Aquestive Therapeutics, Inc.

On June 23, 2026, Julie Krop bought 25,000 shares at $0.71 and sold the same amount at $5.02, with one of these sales being a planned transaction. Additionally, CEO Daniel Barber sold 25,000 shares at $4.16 on June 15, 2026, as part of a pre-arranged trading plan. Gregory Brown also acquired 50,500 shares on June 10, 2026, outside of a planned arrangement.

Other Institutional Activity in Aquestive Therapeutics

Several institutional investors have adjusted their positions in Aquestive Therapeutics recently. RTW Investments, LP increased its holdings by 1,176,471 shares, bringing its total to 7,426,471 shares, valued at about $30.8 million, marking an 18.8% increase. Federated Hermes, Inc. boosted its stake by 907,517 shares, ending with 2,940,339 shares worth approximately $12.2 million, a 44.6% increase. Balyasny Asset Management L.P. significantly increased its position by 1,929,631 shares, resulting in 2,900,570 shares valued at $12.0 million, reflecting a 198.7% increase. Vanguard Capital Management LLC initiated a new position with 4,443,698 shares valued at around $18.4 million.

Aquestive Therapeutics, Inc. Stock Down 0.6%

Shares of Aquestive Therapeutics, Inc. traded near $5.03 on Wednesday. The company has a market capitalization of approximately $592.1 million, with a forward P/E ratio of -10.49, reflecting its current lack of profitability. The stock's beta is 1.451, indicating higher volatility compared to the market. Over the past year, the stock has ranged from a low of $2.93 to a high of $7.55. The 50-day moving average is $4.17, while the 200-day moving average stands at $4.89. The company maintains a strong liquidity position with a current ratio of 4.1 and a quick ratio of 3.7.

Analysts Set New Price Targets

Analysts maintain a positive outlook on Aquestive Therapeutics, with several firms reiterating their 'buy' ratings. Piper Sandler, on November 7, 2025, maintained a 'buy' rating with an $8.00 price target. JMP Securities and Oppenheimer also reiterated 'buy' ratings with targets of $12.00 and $8.00, respectively. The consensus among nine analysts is a 'buy' recommendation, with a mean target price of $8.89.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc. is a pharmaceutical company based in Warren, New Jersey, specializing in developing and commercializing innovative drug delivery systems. The company offers a range of products, including treatments for seizures, opioid dependence, and ADHD. Aquestive is also advancing a proprietary pipeline featuring novel formulations for central nervous system disorders and allergic reactions. Led by CEO Daniel Barber, the company employs 147 people and is committed to providing effective therapies for unmet medical needs.

Bottom Line

Julie Krop's recent purchase of Aquestive Therapeutics shares highlights insider confidence in the company's prospects. While the stock is currently trading at $5.03, the firm's innovative drug delivery technologies and ongoing clinical trials continue to attract investor interest. It's important to note that insider transactions are not always indicative of future performance, and this report reflects past activity as disclosed in filings.